Nkarta (NKTX) Other financing activities (2020 - 2026)

Nkarta (NKTX) posted quarterly Other financing activities of $6000.0 for Q1 2026, down 90.62% quarter-over-quarter from $64000.0 in Q4 2025.

Nkarta (NKTX) Other financing activities (2020 - 2026) Analysis & Trends

Nkarta's Other financing activities history runs 7 years deep, the most recent figure standing at $6000.0 for Q1 2026.

In Q1 2026, Other financing activities changed N/A year-over-year to $6000.0; the TTM figure through Mar 2026 stood at $147000.0 (up 162.55% YoY), while the FY2025 annual figure was $141000.0, down 58.89% from the prior year.
Other financing activities for Q1 2026 stood at $6000.0, down from $64000.0 in the prior quarter.
The five-year high for Other financing activities was $952000.0 in Q3 2022, with the low at -$420000.0 in Q2 2024.
The 5-year median for Other financing activities is $78000.0 (2022), against an average of $172642.9.
Peak annual rise in Other financing activities reached 57700.0% in 2024, while the deepest fall reached 212.6% in 2024.
Nkarta's Other financing activities stood at $32000.0 in 2022, then jumped by 1487.5% to $508000.0 in 2023, then sank by 63.58% to $185000.0 in 2024, then tumbled by 65.41% to $64000.0 in 2025, then slumped by 90.62% to $6000.0 in 2026.
Business Quant data shows NKTX's Other financing activities at $6000.0 in Q1 2026, $64000.0 in Q4 2025, and $77000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Nkarta	201.14 Mn	201.14 Mn	-

Download Data